SV

Street Verdict

Analyst Scorecard

JBCHEPHARM · NSE

JBCHEPHARM

₹2,408.9

-3.87% (-₹97.1)

Prev. close

₹2,506

Volume

47,79,224

Delivery %

66.8%

As of

16 Jul 2026

Price history

₹2,408.9+₹403.5 (+20.12%) · 3M
10 Apr 2026 → 16 Jul 2026
2,0002,1002,2002,3002,4002,50010 Apr06 May01 Jun23 Jun16 Jul
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About JBCHEPHARM

J. B. Chemicals & Pharmaceuticals Limited manufactures and markets pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients (API) in India and internationally. The company's API product portfolio includes diclofenac sodium, diethylamine, acid, and potassium; and nifedipine, atenolol, and cilnidipine; and ciprofloxacin, cetirizine, and meclizine HCI. It also provides dosage forms, such as tablets, capsules, liquids, gels, lozenges, creams, injectables, powder, cold rubs, eye drops, and troches; and soft-centered, powder, medicated, and herbal lozenges, as well as various pharmaceutical dosage forms. In addition, the company offers a range of contrast media products, including x-ray, magnetic resonance imaging (MRI), and ultrasound scanners; and contract manufacturing services. It provides its products to gastroenterology, anti-infectives, wound care, neonatology and pediatrics, genecology, dental, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain-analgesic, dermatology, antivirals, lozenges, and contrast media and radio diagnostic therapeutic areas. J. B. Chemicals & Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Mumbai, India.

Details

CEO

Suresh Amin

Headquarters

Mumbai

Employees

5,602

Key stats

Market cap

₹38,792.59 Cr

P/E ratio (TTM)

54.2

EPS (TTM)

₹44.56

Beta (5Y monthly)

0.04

Shares float

8.16 Cr

EPS · quarter ended Mar 2026

₹6.32

Financial Performance

01 · Financials

0 Cr2000 Cr4000 Cr6000 Cr₹0%10%20%30%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0204060₹FY22FY23FY24FY25

03 · Dividend Profile

051015₹-500%0%500%1000%03 Mar 2022 Sept 2018 Feb 2101 Sept 2123 Feb 2212 Aug 2217 Feb 2317 Aug 2316 Feb 2414 Aug 2407 Feb 2530 Jul 2511 Feb 2629 May 26
Dividend (₹/share)Annual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based · pre-FY23 not filed in verifiable form

-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

Pre-FY23 not filed in verifiable form

0 Cr2000 Cr4000 Cr6000 Cr₹0×0.25×0.5×0.75×1×FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

Pre-FY23 not filed in verifiable form

0 Cr2000 Cr4000 Cr6000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

Pre-FY23 not filed in verifiable form

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹2,042.52 Cr₹2,424.24 Cr₹3,116.51 Cr₹3,447.67 Cr₹3,862.04 Cr₹4,076.20 Cr
EBITDA
₹672.79 Cr₹582.68 Cr₹705.05 Cr₹933.48 Cr₹1,069.12 Cr₹1,140.28 Cr
₹448.52 Cr₹386.04 Cr₹409.84 Cr₹552.63 Cr₹659.58 Cr₹709.47 Cr
Diluted EPS
—₹24.91₹26.17₹34.85₹41.56—

Depreciation & amortisation, Pretax income, Tax provision, Interest expense, Diluted EPS have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹3,553.87 Cr₹3,994.13 Cr₹4,273.78 Cr₹4,968.65 Cr
——₹572.45 Cr₹377.66 Cr₹27.89 Cr₹3.59 Cr
Stockholders' equity
——₹2,480.35 Cr₹2,923.33 Cr₹3,433.32 Cr₹4,159.22 Cr

Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
——₹625.61 Cr₹800.61 Cr₹902.45 Cr₹703.92 Cr
Investing cash flow
——₹-961.79 Cr₹-403.83 Cr₹-295.90 Cr₹-585.88 Cr
——₹356.54 Cr₹-385.49 Cr₹-579.67 Cr₹-123.10 Cr
Capital expenditure
——₹-764.95 Cr₹-261.37 Cr₹-120.31 Cr₹-83.19 Cr
End cash position
——₹76.93 Cr₹88.22 Cr₹115.09 Cr₹110.18 Cr

Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

Index membership

1 index

No stock news captured yet.